Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Hematologic patients with COVID-19 treated with nirmatrelvir/ritonavir showed reduced viral shedding and hospital admissions compared to remdesivir. Oral nirmatrelvir/ritonavir offers an effective early treatment option for high-risk COVID-19 patients.
Area Of Science
- Hematology
- Infectious Diseases
- Virology
Background
- COVID-19 poses significant risks to patients with hematologic malignancies.
- Early antiviral treatment is crucial for managing COVID-19 in immunocompromised populations.
- Understanding the comparative efficacy of different antiviral agents is essential for optimizing patient care.
Purpose Of The Study
- To compare the effectiveness of early antiviral treatment with remdesivir versus nirmatrelvir/ritonavir in hematologic patients with COVID-19.
- To evaluate viral shedding duration, viral load reduction, and clinical outcomes in these patient groups.
- To assess the impact of oral versus intravenous administration on hospitalization rates.
Main Methods
- A non-interventional chart review of high-risk hematologic patients diagnosed with COVID-19.
- Comparison of patients treated with remdesivir (December 2021-April 2022) versus nirmatrelvir/ritonavir (May-August 2022).
- Analysis of baseline characteristics, viral shedding (median duration and Ct values), and hospitalization outcomes.
Main Results
- Eighty-three patients were analyzed (42 remdesivir, 41 nirmatrelvir/ritonavir).
- Nirmatrelvir/ritonavir group showed significantly shorter viral shedding duration (11 vs 18 days, p=0.004) and a greater decrease in viral load within 5 days (median Ct 33 vs 26, p<0.0001).
- Only 9.8% of patients receiving nirmatrelvir/ritonavir required hospitalization compared to all patients on remdesivir.
Conclusions
- Nirmatrelvir/ritonavir treatment in hematologic patients with non-severe COVID-19 led to a faster decrease in viral load and shorter viral shedding.
- Oral administration of nirmatrelvir/ritonavir simplified treatment and significantly reduced the need for hospital admission.
- Both antiviral regimens demonstrated good overall outcomes with no severe adverse events reported.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...